Table 2.

Laboratory characteristics

	Patients with liver disease	HH	ALF	Cirrhosis	Control
Parameter
n	97	52	10	35	22
ICG-PDR, %/min^{b, c, e, f}	5.7 (3.8–7.9)	7 (4.7–8.9)	5.7 (4.8–8.0)	4.1 (3.4–5.9)	20.7 (14.1–25.4)
Bilirubin, mg/dl^{a, b, c, e, f}	3.7 (1.7–9.7)	2.2 (0.8–3.8)	23.8 (9.1–29.2)	7.7 (3.3–16.6)	0.8 (0.6–1.3)
INR^{a, c, d, e, f}	1.8 (1.5–2.3)	1.7 (1.4–2.3)	3.3 (2.1–5.2)	1.7 (1.4–2.2)	1.2 (1.1–1.3)
AST, U/l^{b, c, d, e}	1096 (133–3798)	2667 (1267–5015)	1815 (216–5289)	84 (55–202)	67 (38–418)
ALT, U/l^{b, c, d, e}	743 (76–2119)	1430 (871–2417)	2224 (202–6173)	43 (24–93)	54 (21–176)
Lactate, mmol/l^b	3.5 (2–6.2)	4 (2.3–9.3)	4 (2.3–5.3)	2.5 (1.8–4)	3 (1.8–3.6)
Creatinine, mg/dl^{a, c}	1.5 (1–2.4)	1.7 (1.3–2.3)	0.9 (0.7–1.5)	1.2 (0.8–3.1)	1.1 (0.8–2)

Data are shown as median and IQR

AST aspartate aminotransferase level, ALT alanine aminotransferase level, INR international normalized ratio

^a p < 0.05 HH vs. ALF

^b p < 0.05 HH vs. cirrhosis

^c p < 0.05 HH vs. control

^d p < 0.05 ALF vs. cirrhosis

^e p < 0.05 ALF vs. control

^f p < 0.05 cirrhosis vs. control